Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

D-PLEX 312 - Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX In Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

Next Previous
Trial Profile

D-PLEX 312 - Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX In Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxycycline hyclate (Primary) ; Antibacterials; Antibacterials
  • Indications Surgical wound infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms D-PLEX 312; SHIELD II
  • Sponsors POLYPID

Most Recent Events

  • 17 Jun 2025 According to a POLYPID media release, following successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of 26.7 million dollar ,The Company anticipates that with this additional funding, PolyPids runway would be extended beyond anticipated FDA approval of D-PLEX100.
  • 10 Jun 2025 Status changed from active, no longer recruiting to completed.
  • 09 Jun 2025 According to a POLYPID media release, additional results from the SHIELD II trial will be presented at an upcoming medical conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top